Bullish biotech report from Stifel. Rates, risk on, M&A picking up & pharma desperate to fill patent cliff w/ $1.2 trillion of firepower, “biotech cleanse” (eg more quality names with late stage data after multi-year purge), specialist funds recovered, generalists coming back